Medipost Accelerates Global Push For Lead Stem Cell Therapy
ASEAN, Japan On Near-Term Radar
Executive Summary
South Korean stem cell therapy company Medipost is speeding up the entry of flagship product Cartistem into global markets, with an initial focus on ASEAN countries and Japan and helped by regulators' allowance of early local trials to be waived on the back of strong Korean data.
You may also be interested in...
IVI Warns Of Dire Consequences From COVID-19 Vaccine Inequity
The International Vaccine Institute’s director general warns about COVID-19 vaccine distribution inequalities and its serious consequences, arguing the case for increased global coordination and responsibility for action to improve the situation.
Coronavirus Update: Sotrovimab Filed For EUA In Japan
GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium.
Genome & Co. Bets On Rosy Microbiome Outlook
Korean bioventure Genome & Co. is accelerating growth by acquiring US microbiome CDMO List Labs, following on from its purchase of US microbiome therapeutics firm Scioto last year. With its microbiome pipeline reaching milestones as planned, Genome appears on track for its goal of becoming a fully integrated global biopharma concern.